A safe individualized invasive mechanical ventilation protocol for patients affected by covid-19 can minimize cardiovascular risks and reduce mortality: opinion article
DOI:
https://doi.org/10.62827/fb.v25i2.m958Keywords:
Covid-19; coronavirus; sars-cov-2; mechanical ventilation; cardiovascular diseases.Abstract
Coronavirus is a family of viruses that cause respiratory infections. A new Coronavirus, causing coronavirus disease 2019 (COVID-19), was discovered in China in December 2019. Patients with COVID-19 can present asymptomatic to very severe conditions. In its pathophysiology, there appears to be an important role for the vascular component and pulmonary perfusion and its ideal treatment is still poorly understood. Treatments used in critically ill patients with COVID-19 can have serious cardiovascular repercussions. It is known that around 20% of patients with the severe form of COVID-19 develop myocardial injury, 10% develop myocarditis and 10% to 30% develop shock, and that critical patients often require combined drug therapies. and invasive mechanical ventilation, increasing the risk of cardiovascular and electrolyte disorders, in addition to increasing the risk of death. It was noticed that COVID-19 pneumonia presents an atypical form of ARDS. COVID-19 is a systemic disease that significantly damages the vascular endothelium, causing significant respiratory discomfort. It is noted that patients who develop the severe form of COVID-19 and require invasive ventilatory support have very high mortality rates. These patients require invasive mechanical ventilation (IMV) settings and management strategies that are individualized and unique to each phenotype. The use of appropriate ventilation strategies, through an individualized IMV protocol, can minimize the progression of lung injury. We understand that combined ventilation strategies, through an individualized IMV protocol, can reduce cardiovascular risks, in addition to generating better results in mortality outcomes in the ICU.
References
Brasil. Ministério da Saúde. Coronavírus (COVID-19). Profissionais e gestores de saúde. Brasília: Ministério da Saúde; 2020. Disponível em: https://coronavirus.saude.gov.br. Acesso em: 01 jun de 2023.
World Health Organization. Novel Coronavirus (2019-nCoV) 2020. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Acesso em: 01 jun de 2023.
Associação de Medicina Intensiva Brasileira – AMIB. Recomendações da Associação de Medicina Intensiva Brasileira para a abordagem do COVID-19 em medicina intensiva. Abril de 2020, atualizado em 10 de junho de 2020. Disponível em: https://www.amib.org.br/fileadmin/user_upload/amib/2020/junho/10/Recomendacoes_AMIB-3a_atual.-10.06.pdf. Acesso em: 05 jun de 2023.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368
Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua Bing li xue za zhi = Chinese Journal of Pathology. 2020 May;49(5):411-417.
Alhazzani W, Hylander Moller M, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46:854–887.
Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China [published online ahead of print, 2020 Mar 13]. JAMA Intern Med. 2020;180(7):1-11.
Crivelari NC, Oliveira GQ, Park CHL, et al. Severe Cardiovascular Complications of COVID-19: a Challenge for the Physician. Int J Cardiovasc Sci. 2020;33(5):572-81.
Stas P, Faes D, Noyens P. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. Int J Cardiol. 2008;127(2)
Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173-5.
Esteves V, Zukowski CN, Luca FA, et al. The Association between COVID-19 and ST Elevation Myocardial Infarction: Variable Clinical Presentations on a Case Report Series. Int J Cardiovasc Sci. 2020;33(4):429-35.
Pedro SS, Brito FCF, Scaramello CBV. Challenges in Pharmacological Management of Cardiovascular Diseases in Covid-19: do Benefits Outweigh Risks? Int J Cardiovasc Sci. 2020;33(4):404-11.
Gattinoni L, Coppola S, Cressoni M, et al. Covid-19 does not lead to a “Typical” acute respiratory distress syndrome. Am J Respir Crit Care Med. Epub ahead of print.
Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;14:1–4.
Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA. 2020;323(22):2329–2330.
Robba C, Battaglini D, Ball L, et al. Distinct phenotypes require distinct respiratory management strategies in severe COVID-19 [published online ahead of print, 2020 May 11]. Respir Physiol Neurobiol. 2020;279:103455.
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059.
Delucchi K, Famous KR, Ware LB, et al. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax. 2018;73:439-45.
Jabaudon M, Blondonnet R, Audard J, et al. Recent directions in personalised acute respiratory distress syndrome medicine. Anaesth Crit Care Pain Med. 2018;37:251-8.
Constantin JM, Jabaudon M, Lefrant JY, et al. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomized controlled trial. Lancet Respir Med. 2019;7:870-80.
Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611-20.
Rezoagli E, Bellani G. How I set up positive end-expiratory pressure: evidence- and physiology-based! Crit Care. 2019 Dec 16;23(1):412.
ART investigators writing group. Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2017;318(14):1335-1345.
Pan C, Chen L, Lu C, et al. Lung Recruitability in COVID-19-associated Acute Respiratory Distress Syndrome: A Single-Center Observational Study. Am J Respir Crit Care Med. 2020 May 15;201(10):1294-1297.
Guérin C, Reignier J, Richard JC, et al; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun 6;368(23):2159-68.
Cornejo RA, Díaz JC, Tobar EA, et al. Effects of prone positioning on lung protection in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2013 Aug 15;188(4):440-8.
Sang L, Zheng X, Zhao Z, et al. Lung Recruitment, Individualized PEEP, and Prone Position Ventilation for COVID-19 Associated Severe ARDS: A Single Center Observational Study. Front Med (Lausanne). 2020;7:603943.
Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Roberto Ribeiro da Silva, Leonardo da Costa Silva, Michel Silva Reis (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution 4.0 que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
Autores têm autorização para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
